Neurologic and psychiatric
In 2013, the U.S. Food and Drug Administration (FDA) added a boxed warning to the prescription label of mefloquine regarding the potential for neuropsychiatric side effects that may persist even after discontinuing administration of the medication. In 2013 the FDA stated "Neurologic side effects can occur at any time during drug use, and can last for months to years after the drug is stopped or can be permanent." Neurologic effects include dizziness, loss of balance, seizures, and tinnitus. Psychiatric effects include nightmares, visual hallucinations, auditory hallucinations, anxiety, depression, unusual behavior, and suicidal ideations. Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, insomnia, and vivid dreams) in up to 25%. When some measure of subjective severity is applied to the rating of adverse events, about 11–17% of travelers are incapacitated to some degree. Cardiac
Mefloquine may cause abnormalities with heart rhythms that are visible on electrocardiograms. Combining mefloquine with other drugs that cause similar effects, such as quinine or quinidine, can increase these effects. Combining mefloquine with halofantrine can cause significant increases in QTc intervals. : 10

Contraindications
Mefloquine is contraindicated in those with a previous history of seizures or a recent history of psychiatric disorders. Pregnancy and breastfeeding
Available data suggests that mefloquine is safe and effective for use by pregnant women during all trimesters of pregnancy, and it is widely used for this indication.
Skull bossing is a descriptive term in medical physical examination indicating a protuberance of the skull, most often in the frontal bones of the forehead ("frontal bossing"). Although prominence of the skull bones may be normal, skull bossing may be associated with certain medical conditions, including nutritional, metabolic, hormonal, and hematologic disorders. Frontal bossing
Frontal bossing is the development of an unusually pronounced forehead which may also be associated with a heavier than normal brow ridge. It is caused by enlargement of the frontal bone, often in conjunction with abnormal enlargement of other facial bones, skull, mandible, and bones of the hands and feet. Frontal bossing may be seen in a few rare medical syndromes such as acromegaly – a chronic medical disorder in which the anterior pituitary gland produces excess growth hormone (GH). Frontal bossing may also occur in diseases resulting in chronic anemia, where there is increased hematopoiesis and enlargement of the medullary cavities of the skull. Associated medical disorders
Rickets
Achondroplasia
Acromegaly
Basal cell nevus syndrome
Congenital syphilis
Cleidocranial dysostosis
Crouzon syndrome
Cryopyrin-Associated Periodic Syndrome (CAPS – PFS)
Ectodermal dysplasia
Extramedullary hematopoiesis
Fragile X syndrome
Hurler syndrome
Osteopathia Striata with Cranial Sclerosis
Pfeiffer syndrome
Rubinstein-Taybi syndrome
Russell-Silver syndrome (Russell-Silver dwarf)
Thanatophoric dysplasia
Talfan syndrome
Trimethadione (antiseizure drug) use during pregnancy
Beta-thalassemia (due to expansion of bone marrow secondary to increased hematopoiesis; see Extramedullary hematopoiesis)
Hallermann-Streiff syndrome


== References ==